Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naloxone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 9/20 | 0.71 |
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.71 |
| ▸ | OPRD1 known ✓ | P41143 | 8/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
| ▸ | CYBB | P04839 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naloxone SCHEMBL28209122 | 0.99 | OPRK1 (0.71) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naloxone SCHEMBL4950697 | 0.97 | OPRK1 (0.68) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naloxone SCHEMBL2307300 | 0.95 | OPRK1 (0.74) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naloxone SCHEMBL5657970 | 0.95 | OPRM1 (0.66) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naltrexone SCHEMBL2425204 | 0.91 | OPRM1 (0.71) | OPRK1OPRM1OPRD1CYP2D6LMNA | |
| Oxymorphone SCHEMBL11477430 | 0.91 | OPRD1 (0.72) | OPRK1OPRM1OPRD1MRGPRX2SLC22A1 | |
| Naltrexone SCHEMBL9837116 | 0.91 | OPRK1 (0.68) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Nalorphine SCHEMBL19816078 | 0.91 | OPRK1 (0.63) | OPRK1OPRM1OPRD1CYP2D6CYBB | |
| Naltrexone SCHEMBL29392247 | 0.89 | OPRM1 (0.67) | OPRK1OPRM1OPRD1CYP2D6LMNA | |
| Nalmefene SCHEMBL7574800 | 0.89 | OPRK1 (0.64) | OPRK1OPRM1OPRD1CYP2D6CYBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011139595-A2 | ELONGATED BIODEGRADABLE DEPOT FOR SUSTAINED DRUG RELEASE TO TREAT CHRONIC PELVIC PAIN | MEDTRONIC, INC. (US) | 2011-11-10 | — | — | WO | claimed |
| CN-110478350-A | The application of bulleyaconitine A and its derivative in the preparation inhibition addicted drug of drug | SHANGHAI PINSHAN MEDICAL CONSULTING CO LTD | 2019-11-22 | — | — | CN | disclosed |
| US-8557271-B2 | Drug depot implantable within a joint | WARSAW ORTHOPEDIC, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2011139594-A2 | ARTIFICIAL BURSA FOR INTRA-ARTICULAR DRUG DELIVERY | MEDTRONIC, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139595-A2 | ELONGATED BIODEGRADABLE DEPOT FOR SUSTAINED DRUG RELEASE TO TREAT CHRONIC PELVIC PAIN | MEDTRONIC, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2148864-A2 | FUSED-RING HETEROCYCLE OPIOIDS | Rensselaer Polytechnic Institute (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20100015196-A1 | Drug Depot Implantable Within a Joint | WARSAW ORTHOPEDIC, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2010009111-A2 | A DRUG DEPOT IMPLANTABLE WITHIN A SYNOVIAL JOINT | WARSAW ORTHOPEDIC, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009079211-A1 | A TENDON AND LIGAMENT REPAIR SHEET AND METHODS OF USE | WARSAW ORTHOPEDIC, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090157193-A1 | Tendon and Ligament Repair Sheet and Methods of Use | WARSAW ORTHOPEDIC, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008144394-A2 | FUSED-RING HETEROCYCLE OPIOIDS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2008-11-27 | — | — | WO | disclosed |
| CN-101090891-A | Methods for treating diseases with 4-hydroxybenzomorphans | RENSSELAER POLYTECH INST (US) | 2007-12-19 | — | — | CN | disclosed |
| EP-1817291-A1 | 4-HYDROXYBENZOMORPHANS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006052710-A1 | 4-HYDROXYBENZOMORPHANS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1407771-A1 | SOPHORIDINE AND USE THEREOF AS AN ANALGESIC | Tonghua Fangda Pharmaceuticals, Ltd (CN) | 2004-04-14 | — | — | EP | disclosed |
| EP-1353909-A2 | 8-SUBSTITUTED-2,6-METHANO-3-BENZAZOCINES AND 3-SUBSTITUTED MORPHINANES AS OPIOIDRECEPTOR BINDING AGENTS | Rensselaer Polytechnic Institute (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002036573-A2 | 8- SUBSTITUTED-2, 6-METHANO-3-BENZAZOCINES AND 3-SUBSTITUTED MORPHINANES AS OPIOID RECEPTOR BINDING AGENTS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0454773-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | Bundgaard, Hans (DK) | 1991-11-06 | — | — | EP | disclosed |
| WO-1990008128-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | BUNDGAARD HANS (DK) | 1990-07-26 | — | — | WO | disclosed |